ArticleSurgical endoscopy2026
Clinical outcomes and prognostic significance of endoscopic laryngo-pharyngeal surgery for head and neck squamous cell carcinoma: a retrospective analysis of 111 cases.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck squamous cell carcinoma (HNSCC) have poor outcomes in advanced stages. Early detection and minimally invasive treatment are essential. Endoscopic laryngo-pharyngeal surgery (ELPS), guided by narrowband imaging, is widely used in Asia, but its prognostic value remains unclear.
methodsWe retrospectively analyzed 111 patients with superficial HNSCC who were treated with ELPS between 2014 and 2023. Patient background, treatment results, complications, and prognostic factors were assessed.
resultsThe median observation period was 56 months. En bloc resection was achieved in 96.4% of cases, and the 5-year overall survival (OS) was 91.6%. Tumor thickness > 1000 μm was associated with metastasis in univariate analysis, whereas multivariate analysis identified tumor size > 20 mm and lymphatic invasion as independent predictors. Patients with a body mass index < 18.5 had poorer OS, primarily owing to comorbidities rather than HNSCC. Adverse events occurred in 26.1% of patients, most of which were transient laryngeal edema. One patient required a temporary tracheotomy, but no permanent tracheostomy was needed. ELPS was feasible and safe, even in patients with prior chemoradiotherapy (CRT), as no fatal complications were observed.
conclusionsELPS provides favorable mid- to long-term outcomes and can be safely applied to selected patients, including those with prior CRT. Tumor size and lymphatic invasion are key prognostic factors. These findings support ELPS as a minimally invasive, function-preserving treatment option for superficial HNSCC with careful patient selection.
Indexed as
Identifiers
41286019What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.